Home › Compare › DMCHY vs ABBV
DMCHY yields 6.98% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, DMCHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DMCHY + ABBV for your $10,000?
DMCI Holdings, Inc., through its subsidiaries, engages in the general construction, coal and nickel mining, power generation, real estate development, water concession, and manufacturing businesses in the Philippines and internationally. It operates through seven segments: Construction and Others, Coal Mining, Nickel Mining, Real Estate, On-Grid Power, Off-Grid Power, and Water. It constructs various projects comprising commercial and residential buildings; bridges, power plants, industrial plants; and chapels, hotels, irrigation dams, power transmission lines, and theaters. The company is also involved in the production and trading of concrete products; and handling steel fabrication, and electrical and foundation works. In addition, it engages in the development of mid-income residential properties under the DMCI Homes brand; generation of power through coal-fired and satellite power plants; exploration, mining, development, and sale of coal resources on Semirara Island in Caluya, Antique; mining, extracting, and selling of nickel, chromite, and iron laterite from Berong, Moorsom, and Ulugan mines in Palawan, as well as from Acoje mines in Zambales; and provision of water and sewerage service. The company was incorporated in 1995 and is based in Makati City, the Philippines.
Full DMCHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.